Effect of castor oil emulsion eyedrops on tear film composition and stability

Contact Lens and Anterior Eye

Volumn 33, Issue 2, 2010, Pages 76-82

  Maïssa, Cécile ^a   Guillon, Michel ^a   Simmons, Peter ^b   Vehige, Joseph ^b  

^a OTG Research and Consultancy   (United Kingdom)

^b ALLERGAN INC   (United States)

Author keywords

Castor oil; Dry eye; Eyedrops; Tear film stability; Tear lipids; Triglycerides

Indexed keywords

CASTOR OIL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRY EYE; FEMALE; FOLLOW UP; HUMAN; LACRIMAL FLUID; LIPID BILAYER; MALE; MEAN RESIDENCE TIME; PREVALENCE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TEAR FILM; THERAPY EFFECT; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; CASTOR OIL; DRY EYE SYNDROMES; EMULSIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PILOT PROJECTS; TEARS; TREATMENT OUTCOME;

EID: 77950369464     PISSN: 13670484     EISSN: 14765411     Source Type: Journal    
DOI: 10.1016/j.clae.2009.10.005     Document Type: Article

References (25)

1. Lemp M.A. Report of the National Eye Institute/Industry Workshop on Clinical trials in dry eyes. CLAO J 1995, 21(4):221-232.
2. Hikichi T., Yoshida A., Fukui Y., Hamano T., Ri M., Araki K., et al. Prevalence of dry eye in Japanese eye centers. Graefes Arch Clin Exp Ophthalmol 1995, 233(9):555-558.
3. Doughty M.J., Fonn D., Richter D., Simpson T., Caffery B., Gordon K. A patient questionnaire approach of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci 1997, 74(8):624-631.
4. Bandeen-Roche K., Muñoz B., Tielsch J.M., West S.K., Schein O.D. Self-reported assessment of dry eye in a population-based setting. Invest Ophthalmol Vis Sci 1997, 38(12):2469-2475.
5. Shimmura S., Shimazaki J., Tsubota K. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea 1999, 18(4):408-411.
6. Moss S.E., Klein R., Klein B.E. Prevalence and risk factors for dry eye syndrome. Arch Ophthalmol 2000, 118:1264-1268.
7. Lee A.J., Lee J., Saw S.M., Gazzard G., Koh D., Widjaja D., et al. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol 2002, 86(12):1347-1351.
8. Lin P.Y., Cheng C.Y., Hsu W.M., Tsai S.Y., Lin M.W., Liu J.H., et al. Association between symptoms and signs of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Invest Ophthalmol Vis Sci 2005, 46(5):1593-1598.
9. Lekhanont K., Rojanaporn D., Chuck R.S., Vongthongsri A. Prevalence of dry eye in Bangkok, Thailand. Cornea 2006, 25(10):1162-1167.
10. McCarty C.A., Bansal A.K., Livingston P.M., Stanislavsky Y.L., Taylor H.R. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 1998, 105:1114-1119.
11. Guillon M., Maissa C. Dry eye symptomatology of soft contact lens wearers and nonwearers. Optom Vis Sci 2005, 82(9):829-834.
12. Nelson J.D., Helms H., Fiscella R., Southwell Y., Hirsch J.D. A new look at dry eye disease and its treatment. Adv Ther 2000, 17:84-93.
13. American Academy of Ophthalmology State-of-the-art management of chronic dry eye: proceedings from a scientific roundtable 2006, American Academy of Ophthalmology. http://www.aao.org/.
14. Lemp M.A. Management of dry eye disease. Am J Manag Care 2008, 14:S88-S101.
15. Hom M., Simmons P. Understanding emulsion eyedrop technology. Rev Contact Lenses 2003, 124-126.
16. Sall K., Stevenson O.D., Mundorf T.K., Reis B.L. Two multi-center, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate or severe dry eye disease. Ophthalmology 2000, 107:631-639.
17. Stevenson D., Tauber J., Reis B.L. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group. Ophthalmology 2000, 107:967-974.
18. Vehige J., Carlisle C., Felix C., Simmons P.A., Stoecker J. Clinical trial results of a new emulsion-based dry eye treatment. Invest Ophthalmol Vis Sci 2003, 44:2449. ARVO E-Abstract.
19. Di Pascuale M.A., Goto E., Tseng S.C. Sequential changes of lipid tear film after instillation of a single drop of a new emulsion eye drop in dry eye patients. Ophthalmology 2004, 111(4):783-791.
20. Khanal S., Tomlinson A., Pearce E.I. Efficacy of an emulsion eye drop in the management of mild to moderate dry eyes. Invest Ophthalmol Vis Sci 2005, 46:2038. E-Abstract.
21. Goto E., Shimazaki J., Monden Y., Takano Y., Yagi Y. Low concentration homogenized castor oil eye drops for non inflamed obstructive meibomian gland dysfunction. Ophthalmology 2002, 109(11):2030-2035.
22. Guillon M., Allary J.C., Guillon J.P., Orsborn G. Clinical management of regular replacement. Part 1. Selection of replacement frequency. ICLC 1992, 19:104-120.
23. Guillon J.P., Guillon M. The role of tears in contact lens performance and its measurement. Contact lens practice 1994, 21:453-483. Chapman & Hall Medical, London.
24. Du toit R., Pritchard N., Heffernan S., Simpson T., Fonn D. A comparison of three different scales for rating contact lens handling. Optom Vis Sci 2002, 79:313-320.
25. Bailey I.L., Bullimore M.A., Raasch T.W., Taylor H.R. Clinical grading and the effects of scaling. Invest Ophthalmol Vis Sci 1991, 32:422-432.